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Nonalcoholic fatty liver disease (NAFLD) is a leading liver disease worldwide 
with a prevalence of approximately 25% among adult population. The highest 
prevalence is observed in Middle East and the lowest prevalence in Africa. NAFLD 
is a spectrum of liver disorders ranging from simple steatosis to nonalcoholic 
steatohepatitis (NASH). Pro-inflammatory diet, overweight/obesity, inflammation, 
insulin resistance, prediabetes, type 2 diabetes, dyslipidemia, disrupted gut micro-
biome, and impaired intestinal barrier function are important risk factors associ-
ated with and/or contributing to NAFLD. Gut microbiome is a complex and diverse 
microbial ecosystem essential for the maintenance of human health. It is influenced 
by several factors including diet and medications. Gut microbiome can be disrupted 
in NAFLD. Intestinal epithelial barrier is the largest and most important barrier 
against the external environment and plays an important role in health and disease. 
Several factors including diet and gut microbiome impact intestinal barrier func-
tion. NAFLD can be associated with impaired intestinal barrier function (increased 
intestinal permeability). There are no specific drugs that directly treat NAFLD. The 
first-line therapy of NAFLD is currently lifestyle intervention. Weight loss is an 
important component in the treatment of NAFLD subjects who have excess body 
weight. Gut microbiome and intestinal epithelial barrier are becoming promising 
targets for the treatment of several diseases including NAFLD. In the absence of 
approved pharmacotherapy for the treatment of NAFLD/NASH, in addition to 
lifestyle intervention and weight loss (in case of excess body weight), focus should 
also be on correcting gut microbiome and intestinal permeability (directly and/or 
through gut microbiome modulation) using diet (e.g., low-fat diet, high-fiber diet, 
and Mediterranean diet), prebiotics (nondigestible food ingredients), probiotics 
(nonpathogenic living microorganisms), synbiotics (combination of prebiotics and 
probiotics), and fecal microbiota transplantation (transfer of healthy stool).
Keywords: nonalcoholic fatty liver disease, gut microbiome, intestinal epithelial 
barrier, targeted treatment
1. Introduction
NAFLD is a leading liver disease worldwide with a prevalence of approxi-
mately 25% among adult population. It is the most common cause of chronic 
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liver disease in Western countries. NAFLD is a spectrum of liver disorders rang-
ing from simple steatosis to NASH [1–9].
Pro-inflammatory diet, overweight/obesity, inflammation, insulin resistance, 
prediabetes, type 2 diabetes, dyslipidemia, disrupted gut microbiome, and impaired 
intestinal barrier function are important risk factors associated with and/or con-
tributing to NAFLD [2, 4–27].
In the absence of approved drugs for the treatment of NAFLD/NASH, manage-
ment relies mainly on lifestyle intervention and weight loss (in case of excess body 
weight) [1, 2, 8, 28–30].
Gut microbiome and intestinal epithelial barrier are becoming promising targets 
for the treatment of several diseases including NAFLD [4, 17, 18, 20–22, 24, 25, 31–43].
2. Physiology
2.1 Liver
The liver is the largest visceral organ. It weighs approximately 1.5 kg. 
Macroscopically, the liver is divided into four lobes. The basic functional unit of the 
liver is the liver lobule which includes the hepatocytes. Approximately 30% of the 
liver volume is made up by blood (Figure 1) [44].
The liver is a vital organ. It has numerous important roles including secretion of 
bile (700–1,200 mL/day), metabolism of bilirubin, metabolism of nutrients (e.g., 
glucose homeostasis, fat synthesis, and albumin synthesis), endocrine function 
(e.g., production of angiotensinogen and activation of vitamin D), storage of 
minerals and vitamins (e.g., iron, copper, vitamin A, vitamin B12, and vitamin 
D), hematologic and vascular functions (e.g., hemostatic function and capacity to 
store/release large volume of blood), immunologic and protective functions, and 
metabolic inactivation and detoxification (e.g., catabolism or alteration of hor-
mones, toxins, and drugs) [44].
2.2 Gut microbiome
Gut microbiome is a complex and diverse microbial ecosystem living in the 
digestive tract, mainly in the colon. It is established within the few first years of life 
and contains up to 100 trillion microbes, mainly bacteria (more than 1,000 species) 
but also fungi, protozoa, archaea, and viruses (Figure 2) [45–51].
Gut microbiome is involved in multiple physiological functions and is essential 
for the maintenance of human health [50–57]. It is influenced by several factors 
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2.3 Intestinal epithelial barrier
The intestine is lined by layer of epithelial cells that are connected by cell–cell 
junctions (tight junction, adherens junction, desmosome). These junctions are 
responsible for maintenance of tissue integrity, creation of a barrier, and signal-
ing. The barrier, which is important for tissue homeostasis, controls the passage of 
water, ions, molecules, cells, and pathogens across the epithelial layer. Intestinal 
epithelial barrier is the largest and most important barrier against the external envi-
ronment (barrier between luminal contents and the underlying immune system). 
It covers a surface of approximately 400 m2 and requires approximately 40% of the 
body energy expenditure (Figure 3) [23, 41–43, 70, 71].
Intestinal epithelial barrier is constantly challenged by gut microbiome. It plays 
an important role in health and disease [23, 41–43, 70, 71]. Several factors including 
diet and gut microbiome impact intestinal barrier function [20, 41–43]. A high-
fiber diet has a beneficial effect while a high-fructose diet and a high-fat diet have a 
deleterious effect on intestinal barrier function.
3. NAFLD
3.1 Definition
NAFLD is a liver disease characterized by hepatic steatosis (≥ 5% fat deposit) on 
either imaging or histology, with no excessive alcohol consumption (< 30 g/day for 







viral hepatitis and medications). It is a spectrum of liver disorders ranging from 
simple steatosis to NASH. Up to 30% of NAFLD subjects develop NASH. NASH is 
the aggressive form of NAFLD that can progress to fibrosis, cirrhosis, and hepa-
tocellular cancer. The presence of fibrosis is the strongest predictor of mortality 
(Figure 4) [1–9].
Recently, a consensus of international experts proposed to change the acronym 
NAFLD to MAFLD (metabolic dysfunction-associated fatty liver disease) [72].
3.2 Prevalence
NAFLD is a pandemic with a prevalence of approximately 25% among adult 
population worldwide. The highest prevalence is observed in Middle East and the 
lowest prevalence in Africa. More than 1 billion people are affected by NAFLD 
worldwide (Table 1) [3, 8]. The differences in prevalence can be explained, at least 
partially, by genetic background and lifestyle. NAFLD prevalence continues to rise 
in all age groups, including in the adolescent population, especially in the setting of 
the obesity pandemic.
NAFLD is a sexual dimorphic disease. The prevalence of NAFLD is higher in 
men than in women (protective role of estrogen) [73, 74].
3.3 Pathophysiology
The pathophysiology underlying NAFLD is complex with both non-genetic and 
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Pro-inflammatory diet, overweight/obesity, inflammation, insulin resis-
tance, prediabetes, type 2 diabetes, dyslipidemia, disrupted gut microbiome, 
and impaired intestinal barrier function are important risk factors associated 
with and/or contributing to NAFLD [2, 4–27]. In addition, some miscellaneous 
endocrine disorders including growth hormone (GH) deficiency, hypothyroid-
ism, polycystic ovary syndrome, and hypogonadism and deficiency in epigenetic 
regulators such as sirtuin 1 have been reported as possible contributing factors to 
NAFLD [75–79].
There are several genetic forms of NAFLD including variations in patatin-
like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 
superfamily 2 (TM6SF2), membrane-bound O-acyltransferase domain-containing 
protein 7 (MBOAT7), and glucokinase regulatory protein (GCKR) genes [5, 6].
Excessive fat deposition in the liver (hepatocytes) leading to NAFLD can result 
from one or several combined mechanisms including increased delivery of lipids to 
the liver from diet or adipose tissue, increased de novo synthesis of lipids in the liver, 
decreased hepatic oxidation of fatty acids, and decreased export of triglycerides 
from the liver [7–9].
3.3.1 Pro-inflammatory diet
Various common food components have pro-inflammatory potential and 
by contributing to chronic inflammation, can promote the development of 
NAFLD [10]. They can either directly alter liver metabolism or act through 
disruption of gut microbiome. The Western diet which is a diet rich in saturated 
fat, red meat, fructose, alcohol, and salt is associated with an increased risk 
of NAFLD.
3.3.2 Overweight/obesity, inflammation
Excess body weight (overweight and obesity) is considered as the main cause 
of several abnormalities that are contributing to the pathogenesis of NAFLD (e.g., 
inflammation and insulin resistance). NAFLD is commonly associated with over-
weight/obesity [74]. It is independently associated with both subcutaneous and 
visceral obesity. The adipose tissue inflammation observed in overweight/obesity 
and characterized by increased cytokine production leads to systemic inflammation 
which is responsible for insulin resistance [10, 11, 80]. Clinical studies have shown 
that cellular and molecular adipose tissue inflammation correlate with the degree of 
liver inflammation and the importance of liver disease.
Based on body mass index (BMI), up to approximately 19% of NAFLD subjects 
do not have excess body weight (lean NAFLD) [74, 81, 82].
The prevalence of NAFLD by BMI in a Chinese population of Shanghai is 
reported in Table 2 [74].
BMI NAFLD Prevalence
< 18.5 (n = 445) 0.4%
18.5 to < 24.0 (n = 4,899) 12.7%
24.0 to < 28.0 (n = 2,801) 49.2%
≥ 28.0 (672) 82.4%
Table 2. 
Prevalence of NAFLD by BMI in a Chinese population of Shanghai (n = 8,817).
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3.3.3 Insulin resistance, prediabetes, type 2 diabetes
Insulin resistance plays an important role in the in the development of NAFLD. 
Overweight/obesity and systemic inflammation are responsible for insulin resistance 
which in its turn is an important contributing factor to the pathogenesis of prediabetes, 
type 2 diabetes, and NAFLD [2, 10, 80]. NAFLD is highly correlated with prediabetes 
and type 2 diabetes. There is a reciprocal association between prediabetes/type 2 diabe-
tes and NAFLD [13]. The global prevalence of NAFLD in subjects with prediabetes and 
type 2 diabetes is around 48% and more than 55%, respectively (Figure 5) [5, 10, 12, 15].
3.3.4 Dyslipidemia
Dyslipidemia is a significant risk factor for NAFLD and associated cardiovascu-
lar disease. The mechanism by which dyslipidemia increases the risk of NAFLD may 
be related to an increased accumulation of lipids in the hepatocytes [16].
3.3.5 Disrupted gut microbiome
Profound changes affecting the diversity and the abundance of gut microbi-
ome (dysbiosis) are associated with several metabolic disorders including NAFLD 
[4, 10, 17–25, 83]. Gut microbiome plays a major role in the pathogenesis of 
NAFLD. Disrupted gut microbiome (e.g., increase in pro-inflammatory bacteria 
and decrease in protective bacteria) can promote or aggravate NAFLD through 
several mechanisms including change in intestinal permeability and change in the 
amount of absorbed energy (this can cause overweight/obesity, an important risk 
factor for NAFLD). Microbial metabolites and cell components contribute to the 
development of inflammation and hepatic steatosis.
Several clinical studies have shown the association of qualitative and quantita-
tive changes in gut microbiome (e.g., increased Lactobacillus and Gram-negative 
bacteria) with NAFLD and its severity [4, 17–19, 24, 25]. The increased gut microbi-
ome taxa may produce more short-chain fatty acids (SCFAs), alcohol, and lipopoly-
saccharides (LPS). Increased supply of SCFAs, alcohol, and LPS (endotoxins) into 
the portal circulation is implicated in the pathogenesis of NAFLD and its evolution 
to NASH (promotion of overweight/obesity and inflammation) [17, 20–23].
3.3.6 Impaired intestinal barrier function
Impaired intestinal barrier function causes increased intestinal permeability 
(“leaky gut”) and is associated with several metabolic disorders including NAFLD 
[20, 23, 26, 27, 41–43, 70, 71].
Figure 5. 
There is a strong association between prediabetes/type 2 diabetes and NAFLD.
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Increased intestinal permeability is most likely caused by the disruption of 
intercellular tight junctions of the intestinal epithelium [26, 71]. It promotes trans-
location of bacteria-derived products (e.g., SCFAs, alcohol, and LPS) into the portal 
circulation, exposing the liver to substances capable of inducing hepatic steatosis 
and fibrosis [17, 20–23]. Several studies have reported that serum zonulin, a marker 
of intestinal permeability, correlates significantly with the severity of hepatic 
steatosis in subjects with NAFLD [43].
3.3.7 Miscellaneous endocrine disorders
Several miscellaneous endocrine disorders may contribute to the development 
of secondary NAFLD [75]. GH deficiency through different mechanisms includ-
ing inflammation and insulin resistance may promote NAFLD. Hypothyroidism 
by causing impaired glucose and lipid metabolism and altered energy homeostasis 
can be linked to NAFLD. Polycystic ovary syndrome through multiple factors (e.g., 
obesity, inflammation, insulin resistance, and hyperandrogenism) may promote 
NAFLD. Hypogonadism can be associated with NAFLD through several mecha-
nisms including obesity, insulin resistance, dyslipidemia, estrogen deficiency, and 
dehydroepiandrosterone deficiency.
3.3.8 Sirtuin 1 deficiency
Sirtuins are a group of proteins belonging to the family of silent information 
regulator 2. Humans have seven sirtuins. Sirtuin 1 is widely recognized as an impor-
tant epigenetic regulator involved in multiple biological processes and its deficiency 
contributes to the pathogenesis of several diseases including NAFLD [76–79]. 
Exposure to sirtuin 1 inhibitors (e.g., fructose, alcohol, and LPS) leads to defective 
sirtuin 1 function and can promote NAFLD.
3.3.9 Genetic predisposition
Common genetic forms of NAFLD include variations in PNPLA3, TM6SF2, 
MBOAT7, and GCKR genes (Figure 6). These genetic forms of NAFLD are not asso-
ciated with insulin resistance, type 2 diabetes, and dyslipidemia but can progress to 
NASH, cirrhosis, and hepatocellular cancer [5, 6].
Figure 6. 
Several gene variants can contribute to the pathogenesis of NAFLD.
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3.3.10 Combination of several factors
Several of the above-mentioned factors can be present in subjects with NAFLD, 
especially when they are interrelated. For example, a subject with obesity may have 
inflammation, insulin resistance (with prediabetes or type 2 diabetes), gut microbi-
ome dysbiosis, and leaky gut.
3.4 Diagnosis
NAFLD is a liver disease characterized by hepatic steatosis (≥ 5% fat deposit) on 
either imaging or histology. Several tests (non-invasive and invasive) can be performed 
to support and/or confirm the diagnosis of NAFLD and the presence of fibrosis, and 
optimize the intervention [1, 5, 6, 9, 84–88]. There are several national and international 
guidelines related to the diagnosis and the management of NAFLD (e.g., American 
Association for the Study of Liver Diseases “AASLD”, National Institute for Health and 
Care Excellence “NICE”, European Association for the Study of the Liver “EASL”, Italian 
Association for the Study of the Liver “AISF”, and Asia-Pacific guidelines) [1, 89].
3.4.1 Non-invasive tests
Non-invasive tests of NAFLD include liver biochemistry and imaging  
examination [1, 5, 6, 9, 84–88].
To establish the diagnosis of NAFLD, conventional liver biochemistry is used 
first. It may show an increase in liver enzymes including aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), and gamma-glutamyl transpeptidase 
(GGT). However, up to approximately 75% of subjects with NAFLD may have 
normal liver enzymes. Additional biomarkers and scores have been proposed (e.g., 
cytokeratin-18 fragment, fatty liver index, Zhejiang University index, and NAFLD 
liver fat score) (non-exhaustive list).
Imaging of the liver can be obtained with several tools including ultrasound, 
computed tomography (CT), and magnetic resonance imaging (MRI) (Figure 7). 
Based on most guidelines, abdominal ultrasound should be the first-line examina-
tion for the identification of hepatic steatosis. Although ultrasound has some limita-
tions in morbidly obese subjects and in subjects with liver fat content below 20%, 
it has the advantage of being widely available with low cost. MRI remains the gold 
standard for assessing and quantifying hepatic steatosis since it can detect a liver 
fat content as low as 5%. However, its use is limited due to high cost and a long time 
of execution. Another promising imaging technique is the ultrasonography-based 
transient elastography using continuous attenuation parameter.
Figure 7. 
Abdominal CT scan showing diffuse hepatic steatosis in a subject with NAFLD.
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For the assessment of liver fibrosis, several biomarkers, scores, and imaging 
techniques have been proposed (e.g., AST/ALT ratio, AST to platelet ratio index, 
enhanced liver fibrosis score, NAFLD fibrosis score, and magnetic resonance 
elastography) (non-exhaustive list) [6, 84, 88].
All the non-imaging assessments of NAFLD have limitations and alone cannot 
replace liver biopsy.
3.4.2 Invasive tests
Liver biopsy is the gold standard test in the assessment of NAFLD to diagnose 
NASH and stage liver fibrosis. It is potentially harmful and carries a low risk of 
morbidity and extremely low risk of mortality. Therefore, it should be reserved to 
selected subjects (Figure 8) [1, 90]. One important limitation of liver biopsy is that 
it explores only a small portion of the liver (approximately 1/50,000), not represen-
tative of the entire organ.
3.5 Treatment
Because NAFLD/NASH is associated with increased morbidity and higher risk 
of death mainly related to cardiovascular and liver diseases, it is essential to initiate 
a treatment as soon as the diagnosis is made. In the absence of approved pharmaco-
therapy for the treatment of NAFLD/NASH, the first-line therapy of NAFLD remains 
lifestyle intervention with weight loss (in case of excess body weight) [1, 2, 8, 28–30]. 
Gut microbiome and intestinal epithelial barrier are becoming promising targets for 
the treatment of several diseases including NAFLD [4, 17, 18, 20–22, 24, 25, 31–43]. 
When treating NAFLD/NASH, in addition to lifestyle changes and weight loss (in 
case of excess body weight), focus should also be on correcting gut microbiome and 
intestinal permeability directly and/or through gut microbiome modulation [4, 17, 
18, 20–22, 24, 25, 35–40, 43]. Several drugs for the treatment of NAFLD/NASH are 
currently under investigation [6, 8, 91]. It is also important to treat the associated 
morbidities other than overweight/obesity (e.g., type 2 diabetes and dyslipidemia).
3.5.1 Lifestyle intervention
Lifestyle intervention which includes diet and exercise is the first-line 
therapy in NAFLD but is difficult to maintain (Table 3) [1, 2, 8, 28–30]. Diet is a 
powerful tool in the management of NAFLD. Diet relates to the amount and the 
composition of food that is consumed on a daily basis. There are several types of 
Figure 8. 
Liver histology showing macrovesicular steatosis in a subject with NAFLD.
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diets with different caloric content and different composition of macronutrients, 
fiber, minerals, and vitamins. They include hypocaloric diet, low-carbohydrate 
diet, low-fat, high-protein diet, high-fiber diet, and Mediterranean diet (non-
exhaustive list) [8, 29, 30, 92]. In NAFLD subjects, hypocaloric diet is usually 
a deficit of 500–1,000 kcal/day. For macronutrient composition and according 
to most recommendations, carbohydrate intake should be between 40 and 
50% (with exclusion of fructose from foods and beverages), fat intake no more 
than 30% (with saturated fat below 10%), and protein intake between 15 and 
20% [28]. Even without significant weight loss, anti-inflammatory diets like 
Mediterranean diet (a mainly plant-based low-carbohydrate and high-unsatu-
rated fat diet) have beneficial properties both in the prevention and treatment 
of NAFLD [8, 10, 25, 27–29, 93]. The omega-3 polyunsaturated fatty acids 
present in the Mediterranean diet may reduce hepatic steatosis. A diet contain-
ing sirtuin 1 activators (e.g., magnesium and zinc) can be beneficial in NAFLD 
subjects [79].
The objective in NAFLD subjects with excess body weight is a weight loss of 
7–10%. To achieve weight loss, in addition to lifestyle intervention, other tools 
including drugs, medical devices, and bariatric surgery can also be used when 
needed and indicated [2, 28, 94–97]. Rapid sudden weight loss should be avoided 
(risk of aggravation of liver failure).
Lean NAFLD subjects may have visceral obesity that is not detected by BMI. 
These subjects may also benefit from diet and weight loss.
In addition to the type of diet, the timing and the frequency of the meals may 
also influence NAFLD. It is recommended to consume more daily calories in the 
morning versus the evening and avoid skipping meals [29].
Regular exercise including moderate intensity aerobic activities (3–5 
weekly sessions with approximately 40 minutes per session) and resistance 
 training can reduce hepatic steatosis even without significant weight loss [1, 8, 
28, 29]. Combination of exercise and diet has greater benefit than exercise or 
diet alone.
3.5.2 Gut microbiome modulation
The prevention and management of NAFLD may benefit from modula-
tion and correction of gut microbiome [4, 17, 18, 20–22, 24, 25, 35–40]. Gut 
 microbiome can be modulated through diet, antibiotics, prebiotics, probiot-
ics, synbiotics, and fecal microbiota transplantation [4, 17, 18, 20–22, 24, 25, 
33–40, 58–65]. To optimize the efficacy of these therapies, focus should be on 
the altered gut microbiome (e.g., taxa responsible for high alcohol and LPS 
 production) [17].
Lifestyle Intervention Description
Healthy diet Low-carbohydrate diet, Low-fat diet, High-fiber diet, 
Mediterranean diet, etc.
Diet for weight loss (in case of excess 
body weight)
Hypocaloric diet
Exercise Aerobic activities, Resistance training
Table 3. 
Lifestyle intervention for the treatment of NAFLD.
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3.5.2.1 Diet
Diet is an important tool for the modulation of gut microbiome. The amount of 
daily caloric intake and the content of food significantly affect gut microbiome. A 
diet that is low in calories (when weight loss is needed), low in fat, and high in fiber 
has a favorable effect on weight control and gut microbiome (increase in richness, 
decrease in Firmicutes-to-Bacteroidetes phyla ratio) [58–64].
The diet, through the modulation of gut microbiome, could be beneficial in 
NAFLD subjects [4, 25].
3.5.2.2 Antibiotics
Antibiotics are medications used to fight local or systemic infection [98].
Antibiotics affect gut microbiome [4, 24, 59, 65]. They can deplete or alter gut 
microbiome (e.g., increase in Firmicutes phylum) and reduce liver disease develop-
ment. However, their clinical use is limited since they may eliminate important 
beneficial bacterial species and cause antibiotic resistance.
3.5.2.3 Prebiotics
Prebiotics are chemicals (nondigestible food ingredients) inducing growth 
and/or activity of intestinal bacteria (e.g., inulin, lactulose, and resistant starch) 
[31, 69]. Some dietary fibers are prebiotics [25]. Prebiotics can be found in many 
foods (e.g., leek, asparagus, onion, soybean, apple, and banana) (Figure 9).
Prebiotics can positively modulate gut microbiome and improve NAFLD  
[4, 21, 24, 25, 35]. They lower the production of LPS. Treatment with oligofructose 
(16 g/day for 8 weeks) in subjects with NASH showed a significant decrease of 
AST [35].
3.5.2.4 Probiotics
Probiotics are nonpathogenic living microorganisms with direct or indirect 
effect on gut microbiome [31, 32, 68]. Probiotics can be found in several foods 
(e.g., yogurt, cheese, and milk) (Figure 10).
Probiotics can positively impact gut microbiome and improve NAFLD  
[4, 21, 24, 36–39]. They reduce the production of LPS. Administration of 
Lactobacillus rhamnosus strain GG (12 billion CFU/day) for 8 weeks in children 
with NAFLD showed a significant decrease of ALT [36]. Treatment with VSL#3 
(a mixture of 8 probiotic strains) for 4 months in children with NAFLD demon-
strated a significant decrease of hepatic steatosis [38].
Figure 9. 




Synbiotics are combination of prebiotics and probiotics. They have the potential 
to induce more effects than prebiotics or probiotics used alone.
There are few studies assessing the effects of synbiotics on NAFLD subjects. 
They showed several beneficial effects including reduction of inflammation 
and hepatic steatosis [4, 24, 40]. Administration of Bifidobacterium longum with 
fructo-oligosaccharides for 24 weeks in subjects with NASH showed a signifi-
cant decrease of AST, serum endotoxin, hepatic steatosis, and NASH activity 
index [40].
3.5.2.6 Fecal microbiota transplantation
Fecal microbiota transplantation consists of transfer of feces from a healthy 
donor to a recipient. The addition of healthy stool can be done through  colonoscopy, 
orogastric tube, esophagogastroduodenoscopy, or oral capsule (Figure 11) [99].
Fecal microbiota transplantation is an exciting therapy with important 
potential indications. It was first approved by the United States Food and Drug 
Administration for the treatment of Clostridium difficile infection. Fecal micro-
biota transplantation can modify gut microbiome for the purpose of obesity and 
metabolic disorders management [33, 34]. Clinical studies using fecal microbiota 
transplantation in NAFLD subjects are currently ongoing.
Figure 10. 
Probiotics can be beneficial in the treatment of NAFLD by modulating gut microbiome.
Figure 11. 
Fecal microbiota transplantation has the potential to treat NAFLD by modifying gut microbiome.
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3.5.3 Intestinal permeability correction
Restoring the intestinal epithelial barrier is an attractive therapeutic approach in 
NAFLD subjects. Currently, there is no approved drug for this indication. Intestinal 
permeability can be targeted and corrected directly (with diet) and/or through gut 
microbiome modulation [17, 18, 43].
A study using high-fiber diet for 6 months in subjects with NAFLD showed a 
decrease in intestinal permeability as demonstrated by a reduction of approximately 
90% of serum zonulin, and a significant reduction of liver enzymes (e.g., AST, ALT, 
and GGT) and hepatic steatosis [43].
3.5.4 Drugs
There are no approved drugs for the treatment of NAFLD/NASH. Several 
investigational drugs are currently in various stages of clinical trials. They can 
impact at least four pathways related to NAFLD development and progression 
(hepatic fat accumulation, oxidative stress, gut microbiome, and hepatic fibrosis) 
[7, 8, 91]. Some of these investigational drugs have shown promising preliminary 
results (e.g., lanifibranor, cenicriviroc, and resmetirom) (non-exhaustive list) 
[6, 8, 91].
Any drug that is currently used in the treatment of NAFLD/NASH (e.g., 
antidiabetic drugs, lipid-lowering drugs, and vitamin E) should be con-
sidered as an off-label treatment [1, 2, 6–9, 14–16, 28, 91, 100]. Among the 
antidiabetic drugs, pioglitazone has shown a strong efficacy and became the 
first-line therapy in subjects who have type 2 diabetes and NAFLD [1, 2, 6, 14, 
15, 28, 100].
The summary of different tools available in the United States of America (USA) 
or under investigation for the treatment of NAFLD/NASH is reported in Table 4.
3.5.5 Liver transplantation
NASH is becoming one of the leading causes of liver transplantation. Currently, 
in the USA, NASH ranks as the second most common reason for liver transplanta-
tion after hepatitis C [89].
Tool Description
Lifestyle intervention Diet, Exercise
Anti-obesity drug Xenical®, Qsymia®, Contrave®, Saxenda®
Anti-obesity medical device Lap-Band®, AspireAssist®, Orbera® Intragastric Balloon 
System, TransPyloric Shuttle®, Obalon® Balloon System, 
Plenity®
Bariatric surgery Sleeve gastrectomy, Roux-en-Y gastric bypass
Gut microbiome modulation Diet, Antibiotics, Prebiotics, Probiotics, Synbiotics, Fecal 
microbiota transplantation
Intestinal permeability correction High-fiber diet, Gut microbiome modulation
Off-label drug Antidiabetic drugs, Vitamin E, etc.
Investigational drug Lanifibranor, Cenicriviroc, Resmetirom, etc.
Table 4. 
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4. Conclusions
NAFLD is the most common chronic liver disease worldwide. It is a spectrum 
of liver disorders ranging from simple steatosis to NASH. NAFLD subjects have 
overweight/obesity in the majority of cases and the disease can be associated with 
disrupted gut microbiome and impaired intestinal barrier function.
In the absence of approved pharmacotherapy for the treatment of NAFLD/
NASH, in addition to lifestyle intervention with weight loss (in case of excess body 
weight), targeting gut microbiome and intestinal epithelial barrier with diet, 
prebiotics, probiotics, synbiotics, and fecal microbiota transplantation represents a 
promising novel therapeutic approach.
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